乙基3-氨基-5-己烯酸酯 | 149193-75-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 乙基3-氨基-5-己烯酸酯
• 英文名称: ethyl 3-amino-5-hexenoate
• 英文别名: ethyl 3-amino-54-hexenoate；Ethyl 3-aminohex-5-enoate
• CAS: 149193-75-9
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: FSEAOEBPWOOBNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  乙基3-氨基-5-己烯酸酯 在 双氧水 、 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 3-Benzyloxycarbonylamino-6-hydroxy-hexanoic acid ethyl ester
  参考文献：
  名称：

  Dihydropyrimidinones—a new class of anti-Staphylococcal antibiotics

  摘要：

  We report the synthesis and pharmacological evaluation of new derivatives of natural dipeptide antibiotic TAN-1057 A, B. In the course of this program, we identified novel analogues of the natural product that display similar antibacterial activity and showed improved tolerability. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00880-6
• 作为产物：
  描述：

  4-allylazetidin-2-one 、 乙醇 在 盐酸 作用下， 生成 乙基3-氨基-5-己烯酸酯
  参考文献：
  名称：

  Dihydropyrimidinones—a new class of anti-Staphylococcal antibiotics

  摘要：

  We report the synthesis and pharmacological evaluation of new derivatives of natural dipeptide antibiotic TAN-1057 A, B. In the course of this program, we identified novel analogues of the natural product that display similar antibacterial activity and showed improved tolerability. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00880-6

文献信息

• [EN] SUBSTITUTED (BETA)-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS
  申请人：G.D. SEARLE & CO.

  公开号：WO1993007867A1

  公开（公告）日：1993-04-29

  (EN) Novel substituted beta-amino acid derivatives having general formula (I), are provided, in which e.g. R2 is selected from the group consisting of hydrogen, lower alkyl radicals, lower alkenyl radicals, lower alkynyl radicals, alicyclic hydrocarbon radicals, aromatic hydrocarbon radicals, wherein said radicals are optionally substituted with hydroxy, lower alkoxy, lower alkyl, halogen, nitro, cyano, azido, ureido, ureylene, carboxyl or carbonyl derivatives, trifluoromethyl, acyloxy, alkylthio, arylthio, alkylsulfenyl, arylsulfenyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, trialkylsilyl, aminosulfonyl, dialkylamino, alkanoylamino, aroylamino, phenyl, naphtyl, lower alkynyl which are optionally substituted with one or more of the following: halogen, nitro, lower alkoxy, lower alkyl, trialkylsilyl, azide and phenyl; the invention also pertains to pharmaceutical compositions comprising such derivatives.(FR) L'invention se rapporte à de nouveaux dérivés de bêta-aminoacides substitués, représentés par la formule générale (I), où notamment R2 est choisi dans le groupe constitué par l'hydrogène, par des radicaux d'alkyle inférieur, par des radicaux d'alcényle inférieur, par des radicaux d'alcynyle inférieur, par des radicaux d'hydrocarbure alicyclique, par des radicaux d'hydrocarbure aromatique, ces radicaux étant éventuellement substitués par hydroxy, alcoxy inférieur, alkyle inférieur, halogène, nitro, cyano, azydo, uréido, uréylène, des dérivés carboxyle ou carbonyle, trifluorométhyle, acyloxy, alkylthio, arylthio, alkylsulfényle, arylsulfényle, alkylsulfonyle, arylsulfonyle, amino, alkylamino, trialkylsilyle, aminosulfonyle, dialkylamino, alcanoylamino, aroylamino, phényle, naphtyle, alcynyle inférieur, éventuellement substitués par un ou plusieurs des éléments suivants: halogène, nitro, alcoxy inférieur, alkyle inférieur, trialkylsilyle, azide et phényle; l'invention se rapportant également à des compositions pharmaceutiques comprenant de tels dérivés.

  提供了具有一般式（I）的新型取代β-氨基酸衍生物，其中例如R2是从氢，低烷基基团，低烯基基团，低炔基基团，脂环烃基团，芳香族烃基团中选择的，其中所述基团可以用羟基，低烷氧基，低烷基，卤素，硝基，氰基，偶氮基，脲基，脲基烷基，羧基或羰基衍生物，三氟甲基，酰氧基，烷基硫基，芳基硫基，烷基磺酰基，芳基磺酰基，氨基，烷基氨基，三烷基硅基，氨基磺酰基，二烷基氨基，烷酰胺基，芳酰胺基，苯基，萘基，低炔基，其可以选择地被以下一种或多种替代：卤素，硝基，低烷氧基，低烷基，三烷基硅基，偶氮基和苯基；本发明还涉及包括这样的衍生物的制药组合物。
• Substituted B-amino acid derivatives useful as platelet aggregation inhibitors
  申请人：MONSANTO COMPANY

  公开号：EP0542708A1

  公开（公告）日：1993-05-19

  Novel substituted β amino acid derivatives having the general formula: are provided, in which eg. R² is selected from the group consisting of hydrogen, lower alkyl radicals, lower alkenyl radicals, lower alkynyl radicals, alicyclic hydrocarbon radicals, aromatic hydrocarbon radicals, wherein said radicals are optionally substituted with hydroixy, lower alkoxy, lower alkyl, halogen, nitro, cyano, azido, ureido, ureylene, carboxyl or carbonyl derivatives, trifluoromethyl, acyloxy, alkylthio, arylthio, alkylsulfenyl, arylsulfenyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, trialkylsilyl, aminosulfonyl, dialkylamino, alkanoylamino, aroylamino, phenyl, naphtyl, lower alkynyl which are optionally substituted with one or more of the following: halogen, nitro, lower alkoxy, lower alkyl, trialkylsilyl, azide and phenyl; the invention also pertains to pharmaceutical composition comprising such derivatives.

  具有通式的新型取代 β 氨基酸衍生物： 的新型取代 β 氨基酸衍生物，其中 R²选自由氢、低级烷基、低级烯基、低级炔基、脂环烃基、芳香烃基组成的组，其中所述基可任选被羟基、低级烷氧基、低级烷基、卤素、硝基、氰基、叠氮基、脲基、脲烯基取代、羧基或羰基衍生物、三氟甲基、酰氧基、烷硫基、芳硫基、烷基亚磺酰基、芳基亚磺酰基、烷基磺酰基、芳基磺酰基、氨基、烷基氨基、三烷基硅基、氨基磺酰基、二烷基氨基、烷酰氨基、芳基氨基、苯基、萘基、低级炔基，这些基可任选被以下一种或多种物质取代：卤素、硝基、低级烷氧基、低级烷基、三烷基硅基、叠氮化物和苯基；本发明还涉及包含这些衍生物的药物组合物。
• Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists
  作者：Jeffery A. Zablocki、Joseph G. Rico、Robert B. Garland、Thomas E. Rogers、Kenneth Williams、Lori A. Schretzman、Shashidhar A. Rao、Philippe R. Bovy、Foe S. Tjoeng

  DOI：10.1021/jm00013a014

  日期：1995.6

  Our initial orally active fibrinogen receptor antagonist benzamidinopentanoyl (BAP) series which was discovered through truncation of our iv antiplatelet agent (SC-52012) demonstrated modest oral activity in canine studies (ethyl [5-(4-amidinophenyl)pentanoyl]3-3-amino-3 pyridyl)propionate, 1e). Introduction of an amide bond adjacent to the benzamidine led to a novel series with an (aminobenzamidino)succinyl (ABAS) Arg-Gly surrogate that had improved in vitro potency (5-17 times) relative to the BAP series. Four ester prodrug/acid active metabolite pairs (2a/2e, 60a/60e, 62a/62e, 63a/63e) from the ABAS series which varied in their 3-substituent on the beta-amino ester ''aspartate mimetic'' were prepared in enantiomerically enriched form (>95:5), and they were evaluated in canine studies for their ability to block collagen-induced aggregation in platelet-rich plasma, the elimination profile (t(1/2) beta-phase), repeated oral dosing studies, and oral systemic availability. Of the four ester prodrug/acid active metabolite pairs, 2e/2a (SC-54684A/SC-54701A) had the most favorable properties in the above studies with an IC50 = 67 +/- 5 nM (dog platelet-rich plasma, collagen), t(1/2) beta = 1.6 h tester) and 6.5 h (acid), no adverse effects upon repeated dosing, and a drug oral systemic availability of 62% (area under curve (AUG) of acid 2a (drug) following ig administration of ester 2e (prodrug, 2.5 mg/kg) divided by AUC of acid 2a (drug) following iv administration of ester 2e (prodrug, 2.5 mg/kg) as determined by HPLRC). In further pharmacokinetic studies using nonlabeled 2e/2a, the oral systemic availability tester 2e ig/ester 2e iv) of 2e was measured to be in the range of 44.7-53.0%. The more biologically relevant oral systemic availability tester 2e ig/acid 2a iv) of 2e was found to be in the range of 22.0-26.4%. A pharmacophore model. based on inhibitors from several different benzamidine classes including 2a (ABAS class) was developed using a combination of molecular modeling (MM2) and pharmacophore identification (APOLLO) methods.
• Design and Synthesis of Potent and Selective Inhibitors of Integrin VLA-4
  作者：Sompong Wattanasin、Beat Weidmann、Didier Roche、Stewart Myers、Amy Xing、Qin Guo、Michael Sabio、Peter von Matt、Ronald Hugo、Susan Maida、Philip Lake、Marla Weetall

  DOI：10.1016/s0960-894x(01)00586-8

  日期：2001.11

  The synthesis and identification of a novel series of inhibitors of integrin VLA-4 are described. Their in vitro activity and selectivity against closely related integrins are also presented. (C) 2001 Elsevier Science Ltd. All rights reserved.
• Substituted beta-amino acid derivatives useful as platelet aggregation inhibitors
  申请人：MONSANTO COMPANY

  公开号：EP0542708B1

  公开（公告）日：2001-05-30